other material
confidence high
sentiment positive
materiality 0.60
Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee
RECURSION PHARMACEUTICALS, INC.
- Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.
- Recursion to receive $30 million Acceptance Fee from Roche.
- Option exercised by Genentech, a member of the Roche Group.